Gene expression signature after one dose of neoadjuvant pembrolizumab associated with tumor response in head and neck squamous cell carcinoma (HNSCC).

Eejung Kim(Broad Institute), Trisha M. Wise‐Draper(University of Cincinnati), Benjamin H. Hinrichs(University of Cincinnati), Yash Patil(University of Cincinnati), Vinita Takiar(University of Cincinnati), Sarah Palackdharry(University of Cincinnati), Jonathan R. Mark(University of Cincinnati), Edith M. Janssen(Springhouse), Alice L. Tang(University of Cincinnati), Benyamin Yaniv(University of Massachusetts Chan Medical School), Keith Wilson(Cardiff University), Laura Conforti(University of Cincinnati)
Journal of Clinical Oncology
May 20, 2018
Cited by 4


Related Papers